Antifungal Susceptibility ofCandidaBiofilms: Unique Efficacy of Amphotericin B Lipid Formulations and Echinocandins
Authors:
Top Cited Papers
Open Access
- 1 June 2002
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (6) , 1773-1780
Abstract
Biofilms, likely the predominant mode of device-related microbial infection, exhibit resistance to antimicrobial agents. Evidence suggests thatCandidabiofilms have dramatically reduced susceptibility to antifungal drugs. We examined antifungal susceptibilities ofCandida albicansandCandida parapsilosisbiofilms grown on a bioprosthetic model. In addition to conventional agents, we determined if new antifungal agents (triazoles, amphotericin B lipid formulations, and echinocandins) have activities againstCandidabiofilms. We also explored effects of preincubation ofC. albicanscells with subinhibitory concentrations (sub-MICs) of drugs to see if they could modify subsequent biofilm formation. Finally, we used confocal scanning laser microscopy (CSLM) to image planktonic- and biofilm-exposed blastospores to examine drug effects on cell structure.Candidabiofilms were formed on silicone elastomer and quantified by tetrazolium and dry weight (DW) assays. Susceptibility testing of fluconazole, nystatin, chlorhexidine, terbenafine, amphotericin B (AMB), and the triazoles voriconazole (VRC) and ravuconazole revealed resistance in allCandidaisolates examined when grown as biofilms, compared to planktonic forms. In contrast, lipid formulations of AMB (liposomal AMB and AMB lipid complex [ABLC]) and echinocandins (caspofungin [Casp] and micafungin) showed activity againstCandidabiofilms. Preincubation ofC. albicanscells with sub-MIC levels of antifungals decreased the ability of cells to subsequently form biofilm (measured by DW;P< 0.0005). CSLM analysis of planktonic and biofilm-associated blastospores showed treatment with VRC, Casp, and ABLC resulted in morphological alterations, which differed with each agent. In conclusion, our data show thatCandidabiofilms show unique susceptibilities to echinocandins and AMB lipid formulations.Keywords
This publication has 67 references indexed in Scilit:
- Evaluation of Etest Method for Determining Caspofungin (MK-0991) Susceptibilities of 726 Clinical Isolates of Candida SpeciesJournal of Clinical Microbiology, 2001
- Biofilm Formation by the Fungal Pathogen Candida albicans : Development, Architecture, and Drug ResistanceJournal of Bacteriology, 2001
- Riddle of Biofilm ResistanceAntimicrobial Agents and Chemotherapy, 2001
- Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin BJournal of Antimicrobial Chemotherapy, 2000
- Practice Guidelines for the Treatment of CandidiasisClinical Infectious Diseases, 2000
- Risk factors for candidemia in Neonatal Intensive Care Unit patientsThe Pediatric Infectious Disease Journal, 2000
- Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes☆Diagnostic Microbiology and Infectious Disease, 2000
- In Vitro Activity of the New Echinocandin Antifungal, MK-0991, against Common and Uncommon Clinical Isolates ofEuropean Journal of Clinical Microbiology & Infectious Diseases, 1999
- Activity of MK-0991 (l-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.Diagnostic Microbiology and Infectious Disease, 1998
- Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicansJournal of Antimicrobial Chemotherapy, 1995